Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BTK C481X |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05168930 | Phase II | Venetoclax + Zanubrutinib | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | Recruiting | USA | 0 |
| NCT04305444 | Phase II | DTRMWXHS-12 + Everolimus + Pomalidomide | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | Terminated | USA | 0 |
| NCT02427451 | Phase Ib/II | Ibrutinib + Obinutuzumab + Venetoclax | Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
| NCT01644253 | Phase I | Idelalisib + Otlertuzumab + Rituximab Otlertuzumab + Rituximab Obinutuzumab + Otlertuzumab Ibrutinib + Otlertuzumab Bendamustine + Otlertuzumab | Phase 1b Safety and Efficacy Study of TRU-016 | Terminated | USA | 0 |
| NCT04043845 | Phase I | Ibrutinib + LY3214996 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Withdrawn | 0 | |
| NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Completed | USA | SWE | POL | ITA | GBR | FRA | CHE | AUS | 2 |
| NCT04115059 | Phase I | Dasatinib | Dasatinib In Waldenstrom Macroglobulinemia | Terminated | USA | 0 |